EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan

Naoki Tani iD, Maxine Dibué iD, Ryan Verner iD, Stephany Mai Nishikawa iD, Charles Gordon iD, Kensuke Kawai iD, Haruhiko Kishima iD

Epilepsia Open · 2024-12 · 9 (6) · 2154-2163

DOI: 10.1002/epi4.13025 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia Open, online erschienen am 10.09.2024. Verfasst von Naoki Tani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Quality of Life, Drug Resistant Epilepsy, Seizures. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nihon Koden Corporation, LivaNova PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Amount of seizure‐free days is a critical determinant of quality of life (QoL) in patients with drug‐resistant epilepsy (DRE). The fractions of patients experiencing prolonged periods of seizure freedom with adjunctive vagus nerve stimulation (VNS) have yet to be assessed on a large scale.

Methods

Retrospective analysis of patients in the Japanese VNS prospective observational registry who experienced at least 1 year of seizure freedom from all seizures, focal seizures, or tonic–clonic seizures (TCS), as well as patient‐reported change in QoL in these groups.

Results

The study included 362 patients with DRE, 147 were female (40.6%), and the median age at VNS implant was 23.0 years (range: 1.0–73.0). A total of 225 patients reported focal seizures and 184 patients reported TCS. After 36 months of adjunctive VNS, the cumulative proportion of patients experiencing at least 1 year of complete seizure freedom was 11% (38/356) with an average duration of seizure freedom of 19.4 months. In patients with focal seizures, 25% ( n = 57/225) experienced at least 1 year of freedom from focal seizures with an average duration of 24.8 months. Higher cumulative rates of freedom from TCS were observed: 55% ( n = 101/184) experienced at least 1 year without TCS with an average duration of TCS‐free periods of 28.9 months. 82.1% of patients with 12‐month complete seizure freedom reported markedly improved or improved QoL compared with 51.9% of patients who were not seizure‐free. QoL changes in patients with 12‐month seizure freedom from TCS and focal seizures were similar: 61.8% and 63% of respective patients reported either markedly improved or improved QoL at 36 months. Significance Complete seizure freedom is rare in patients treated with VNS; however, this analysis found approximately half of patients who experienced TCS prior to VNS experienced prolonged periods of freedom from TCS with adjunctive VNS. Plain Language Summary We studied patients in Japan with epilepsy that is difficult to treat. To understand if adding vagus nerve stimulation (VNS) helps such patients, we looked at which patients stopped having all seizures or stopped having a specific seizure type (such as tonic–clonic seizures or focal seizures), and how long these periods lasted. With VNS treatment, about 2 out of 4 patients with tonic–clonic seizures and 1 out of 4 patients with focal seizures had more time without these seizure types. Without seizures, patients felt better about their daily lives. Even patients who still had seizures felt better about their daily lives after 3 years of VNS treatment. Trial Registration The clinical trial registry number is UMIN000014728.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vagus Nerve StimulationQuality of LifeDrug Resistant EpilepsySeizuresHumansFemaleMaleAdultAdolescentJapanChildYoung AdultRetrospective StudiesMiddle AgedChild, PreschoolInfantAgedTreatment OutcomeRegistriesCombined Modality Therapy

Stichwörter der Autor:innen

quality of lifeseizure freedomseizure reductionsudden unexpected death in epilepsytonic–clonic seizuresvagus nerve stimulation

Autor:innen und Institutionen

  • Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
  • Medical and Clinical Affairs Neuromodulation, LivaNova PLC, London, UK.
  • Statistics and Data Management, LivaNova PLC, London, UK.
  • Department of Neurosurgery and Epilepsy Center, Jichi Medical University, Shimotsuke, Japan.

ORCID-Profile: Naoki Tani, Maxine Dibué, Ryan Verner, Stephany Mai Nishikawa, Charles Gordon, Kensuke Kawai, Haruhiko Kishima

Förderung

  • Nihon Koden Corporation
  • LivaNova PLC

Zitieren

APA

Tani, N., Dibué, M., Verner, R., Nishikawa, S. M., Gordon, C., Kawai, K., & Kishima, H. (2024). One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan. Epilepsia Open, 9(6), 2154-2163. https://doi.org/10.1002/epi4.13025

Vancouver

Tani N, Dibué M, Verner R, Nishikawa SM, Gordon C, Kawai K, et al. One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan. Epilepsia Open. 2024;9(6):2154-2163. doi:10.1002/epi4.13025

BibTeX
@article{Tani2024,
  author = {Tani, Naoki and Dibué, Maxine and Verner, Ryan and Nishikawa, Stephany Mai and Gordon, Charles and Kawai, Kensuke and Kishima, Haruhiko},
  title = {One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan},
  journal = {Epilepsia Open},
  year = {2024},
  volume = {9},
  number = {6},
  pages = {2154--2163},
  doi = {10.1002/epi4.13025}
}
Kostenlos starten →